ENTOD Pharmaceuticals, a trailblazer in the Indian pharmaceutical industry, achieves a significant milestone with the approval of PresVu, a groundbreaking treatment for presbyopia, by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu emerges as the first-of-its-kind eye drop in India, designed to address the need for reading glasses among individuals facing presbyopia, a prevalent age-related vision impairment affecting millions.

Presbyopia, characterised by blurred near vision due to the decreased flexibility of the eye's natural lens, primarily impacts individuals aged 40 and above. With PresVu, ENTOD Pharmaceuticals introduces a game-changing intervention, offering swift relief and temporary correction of vision problems associated with presbyopia. Leveraging innovative dynamic buffer technology developed through their DSIR-approved R&D facility, PresVu eye drops adjust rapidly to tear pH, ensuring sustained efficacy and safety for long-term use.

The journey towards the development of these eye drops culminated in late 2022, followed by rigorous clinical testing in India. Phase 3 clinical trials conducted in India and the US have demonstrated PresVu's efficacy in enhancing close-up vision within minutes of application, with effects lasting up to six hours. This groundbreaking formulation holds immense promise for individuals aged 40 to 55 with mild to intermediate presbyopia, providing a viable alternative to traditional interventions like reading glasses.

Mr. Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, expressed his enthusiasm, stating, "The approval of PresVu represents a significant breakthrough in our mission to redefine eye care in India. As the innovator in presbyopia treatment in India, we aim to empower individuals to regain visual clarity and independence, free from the constraints of reading glasses. As part of our commitment to 'Make in India,' we are dedicated to manufacturing PresVu eye drops at an affordable price, ensuring accessibility to all segments of society."

Mr. Mohammed Kamil Khan, Corporate Marketing Head at ENTOD Pharmaceuticals, emphasised the transformative potential of PresVu, stating, "PresVu eye drops harness the eye's natural mechanisms to expand the depth of field and focus, enabling individuals to adapt to different ranges naturally. Moreover, our dynamic buffer technology ensures optimal performance and safety, making PresVu an ideal long-term treatment for presbyopia management."

Dr. Vardhaman Kankariya, Director of Asian Eye Hospital, Pune, echoed the sentiments, remarking, "The potential of PresVu to significantly enhance the quality of life for individuals grappling with presbyopia is truly remarkable. It offers them a renewed sense of freedom and visual clarity, marking a significant advancement in ophthalmic care. As we strive to provide the best possible treatments for our patients, innovative treatments like PresVu hold immense promise for addressing age-related vision challenges. We look forward to witnessing the positive impact it will have on countless lives, empowering individuals to enjoy a clearer and more vibrant outlook on the world."

The approval of PresVu underscores ENTOD Pharmaceuticals' unwavering commitment to advancing eye care and improving the quality of life for individuals across India. As PresVu prepares for commercialization, ENTOD remains steadfast in its dedication to innovation and excellence in the field of pharmaceuticals. PresVu stands poised to revolutionise presbyopia management, offering hope and freedom to millions nationwide.

DTMT Network 

ENTOD Pharmaceuticals, a trailblazer in the Indian pharmaceutical industry, achieves a significant milestone with the approval of PresVu, a groundbreaking treatment for presbyopia, by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu emerges as the first-of-its-kind eye drop in India, designed to address the need for reading glasses among individuals facing presbyopia, a prevalent age-related vision impairment affecting millions.

Presbyopia, characterised by blurred near vision due to the decreased flexibility of the eye's natural lens, primarily impacts individuals aged 40 and above. With PresVu, ENTOD Pharmaceuticals introduces a game-changing intervention, offering swift relief and temporary correction of vision problems associated with presbyopia. Leveraging innovative dynamic buffer technology developed through their DSIR-approved R&D facility, PresVu eye drops adjust rapidly to tear pH, ensuring sustained efficacy and safety for long-term use.

The journey towards the development of these eye drops culminated in late 2022, followed by rigorous clinical testing in India. Phase 3 clinical trials conducted in India and the US have demonstrated PresVu's efficacy in enhancing close-up vision within minutes of application, with effects lasting up to six hours. This groundbreaking formulation holds immense promise for individuals aged 40 to 55 with mild to intermediate presbyopia, providing a viable alternative to traditional interventions like reading glasses.

Mr. Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, expressed his enthusiasm, stating, "The approval of PresVu represents a significant breakthrough in our mission to redefine eye care in India. As the innovator in presbyopia treatment in India, we aim to empower individuals to regain visual clarity and independence, free from the constraints of reading glasses. As part of our commitment to 'Make in India,' we are dedicated to manufacturing PresVu eye drops at an affordable price, ensuring accessibility to all segments of society."

Mr. Mohammed Kamil Khan, Corporate Marketing Head at ENTOD Pharmaceuticals, emphasised the transformative potential of PresVu, stating, "PresVu eye drops harness the eye's natural mechanisms to expand the depth of field and focus, enabling individuals to adapt to different ranges naturally. Moreover, our dynamic buffer technology ensures optimal performance and safety, making PresVu an ideal long-term treatment for presbyopia management."

Dr. Vardhaman Kankariya, Director of Asian Eye Hospital, Pune, echoed the sentiments, remarking, "The potential of PresVu to significantly enhance the quality of life for individuals grappling with presbyopia is truly remarkable. It offers them a renewed sense of freedom and visual clarity, marking a significant advancement in ophthalmic care. As we strive to provide the best possible treatments for our patients, innovative treatments like PresVu hold immense promise for addressing age-related vision challenges. We look forward to witnessing the positive impact it will have on countless lives, empowering individuals to enjoy a clearer and more vibrant outlook on the world."

The approval of PresVu underscores ENTOD Pharmaceuticals' unwavering commitment to advancing eye care and improving the quality of life for individuals across India. As PresVu prepares for commercialization, ENTOD remains steadfast in its dedication to innovation and excellence in the field of pharmaceuticals. PresVu stands poised to revolutionise presbyopia management, offering hope and freedom to millions nationwide.